<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127633">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01749475</url>
  </required_header>
  <id_info>
    <org_study_id>HYPTEE</org_study_id>
    <nct_id>NCT01749475</nct_id>
  </id_info>
  <brief_title>Hypnosis vs Midazolam for Sedation for TEE</brief_title>
  <official_title>Hypnosis for Sedation in Transesophageal Echocardiography: Comparison With Midazolam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the reports on hypnosis in the literature have focused on pain control during minor
      operations. With this study we aimed to evaluate the role of hypnosis on sedation for
      transesophageal echocardiography and compare it with commonly used sedative midazolam.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sedative effects of hypnotherapy and the drug &quot;midazolam&quot; indicated by anxiety scores and bispectral index (BIS) monitoring</measure>
    <time_frame>during transesophageal echocardiography</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of alertness after sedation with continuous performance test (CPT)</measure>
    <time_frame>the same time frame</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Clinical Indications for Transesophageal Echocardiography</condition>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>hypnosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.</description>
    <arm_group_label>midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypnotherapy</intervention_name>
    <description>A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.</description>
    <arm_group_label>hypnosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients admitting to cardiology department for transesophageal echocardiography (TEE)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indications for TEE

          -  American Society of Anesthesiology (ASA) physical status I-III

        Exclusion Criteria:

          -  mental illness,

          -  psychotropic medication use,

          -  hypersensitivity to drugs

          -  a body mass index over 30.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bakirkoy Dr Sadi Konuk Training Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 27, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
